Highlighting DuetTx Platform & Discovery of First-in-Class Dual Payload ADCs Advancing to the Clinic

• Laying out innovation-led approach to novel ADC therapies leveraging dual payload and target design
• Assessing design rationale and differentiated advantages of proprietary DuetTx platform
• Introducing preclinical efficacy and safety profile of dual payload ADC assets as first-in-generation advancing to clinical development

Speakers:

Shi Chen

Associate Director, Oncology Biology

Innovent Biologics